Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia

Article ID	Journal	Published Year	Pages	File Type
5844423	Progress in Neuro-Psychopharmacology and Biological Psychiatry	2014	9 Pages	PDF

Abstract

This study confirms the findings from earlier pali ER global relapse-prevention studies and demonstrates that pali ER treatment (3-12Â mg) is efficacious over the long-term and significantly delays relapse in Chinese patients with schizophrenia. No new safety signals were detected in this population.

Keywords

SAS PANSS Paliperidone extended-release DSM-IV-TR CGI-S ANCOVA Barnes Akathisia Rating Scale LOCF PSP SGAs EPS IDMC C-SSRS Personal and Social Performance scale TEAEs Extrapyramidal symptom Schizophrenia electrocardiogram ECG Extended release standard deviation AIMS ITT analysis of covariance baseline standard error Double blind body mass index BMI adverse event Treatment-emergent adverse events confidence interval Intent-to-treat last observation carried forward Columbia Suicide Severity Rating Scale Abnormal Involuntary Movement Scale positive and negative syndrome scale Bars hazards ratio Second generation antipsychotics Symptoms Paliperidone Stabilization Chinese Independent Data Monitoring Committee